Möchten Sie immer auf dem neuesten Stand bleiben?

AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong...

Price reflects an attractive value to Novartis  Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions  Sale of JV in a non-core segment in best...

Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN)  Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN   Shannon Klinger...

Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase...

Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT)   Advanced Accelerator Applications is a newly established subsidiary of Novartis   Lutathera expands...

As filed with the US Securities and Exchange Commission on January 24, 2018 ...

Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1...

Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development...

Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of...

Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart...